5-Isopropyl-cumalin | 87616-06-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 5-Isopropyl-cumalin
• 英文别名: 5-isopropyl-pyran-2-one；5-Propan-2-ylpyran-2-one
• CAS: 87616-06-6
• 化学式: C₈H₁₀O₂
• 分子量: 138.166
• InChiKey: IFMHMZOKZYSRDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
  申请人：QIAN XIANGPING

  公开号：US20120196842A1

  公开（公告）日：2012-08-02

  Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

  本文描述了新化合物、制药组合物和治疗癌症的方法。
• CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF
  申请人：Suzhou NeuPharma Co., Ltd

  公开号：EP3453714A2

  公开（公告）日：2019-03-13

  Disclosed are the compounds of formula (I), wherein R1-R13, W1, W2 and Z are as defined in the claims, as well as pharmaceutical compositions thereof, and these compounds for use in the treatment of cancer.

  公开了式 (I) 的化合物（其中 R1-R13、W1、W2 和 Z 如权利要求中定义）及其药物组合物，以及用于治疗癌症的这些化合物。
• Certain chemical entities, compositions, and methods
  申请人：NeuPharma, Inc.

  公开号：US10344048B2

  公开（公告）日：2019-07-09

  Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

  介绍了治疗癌症的新型化合物、药物组合物和方法的化学实体。
• Substituted Diaza-Spiro-[5.5]-Undecane Derivaties and Their Use as Neurokinin Antagonists
  申请人：Janssens Eduard Frans

  公开号：US20070232636A1

  公开（公告）日：2007-10-04

  This invention concerns substituted diaza-spiro-[5.5]-undecane derivatives having neurokinin antagonistic activity, in particular NK 1 antagonistic activity, a combined NK 1 /NK 2 antagonistic activity, a combined NK 1 /NK 3 antagonistic activity and a combined NK 1 /NK 2 /NK 3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, COPD and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
• Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders
  申请人：Khodadoust Mehran

  公开号：US20110076278A1

  公开（公告）日：2011-03-31

  Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor-1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized by ischmia.